The U.S. Food and Drug Administration (FDA) approved Soliris (eculizumab), the first product for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare type of blood disorder that can lead to disability and premature death. Soliris is classified as an Orphan Drug and is a new molecular entity containing an ingredient not previously marketed in the United States.
The U.S. Food and Drug Administration (FDA) cleared for marketing a test that uses molecular biology to quickly detect the presence of viral meningitis.
Researchers at Yale have identified multiple pathogenic “alien islands” in the genome of the A. baumannii, bacteria that has been responsible for new and highly drug-resistant infections in combat troops in the Middle East, according to a report in the March 1 issue of Genes and Development.
A new report from the World Health Organization (WHO) shows that neurological disorders, ranging from epilepsy to Alzheimer disease, from stroke to headache, affect up to one billion people worldwide.
Two enzymes in meningitis bacteria which prevent the body from successfully fighting off the disease, and make the infection extremelyvirulent, have been identified in new research published today.
Blood poisoning and meningitis are acute life-threatening infections that are often caused by meningococcus bacteria. The course of the disease is still relatively unknown, but a research team at Uppsala University led by Professor Ann-Beth Jonsson has managed to monitor the movements of the bacteria and glean information that may help in the development of new vaccines against the diseases. The study is being published in the new issue of the online journal PLoS ONE.
Funding from Canada, Italy, Norway and the UK may save millions of poor children and pave the way for rapid introduction of future vaccines, including AIDS, malaria and TB.
Today the Rhode Island Department of Health was notified of a confirmed case of Neisseria Meningococcemia in a resident of an assisted living residence in Rhode Island (resident did not develop meningitis).
CNRS France and a team of Portuguese researchers at the Istitut Pasteur have just identified a protein in a micro-organism which allows it to colonise a host by modulating its immune system and may show the way to combat Group B Streptococci.
CRNS and the Institut Pasteur conducted research in France on patients diagnosed with cryptococcosis which ranks second among fatal opportunistic infections in patients infected by HIV and who are profoundly immunosuppressed.